In a historic development for oncology, Revolution Medicines (RevMed) has secured US Food and Drug Administration (FDA) approval for its pancreatic cancer drug daraxonrasib, marking the first targeted therapy to address the disease's key molecular driver. This milestone represents one of the most significant breakthroughs in pancreatic cancer treatment in decades.
Clinical trial data released by the FDA demonstrated that daraxonrasib extended median survival to 13.2 months for patients with aggressive pancreatic cancer, nearly doubling the 6.7 months observed in those receiving standard chemotherapy. FDA Acting Chief Kyle Diamantas stated that "today's approval provides a vital new option for patients facing this extraordinarily aggressive and historically difficult-to-treat cancer."
The drug, marketed under the brand name Rasonque, carries an annual list price exceeding $475,000. It is approved for patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are ineligible for such treatment. Following the announcement, RevMed's shares climbed 2.5% during intraday trading, bringing year-to-date gains to over 100%, with the company's market capitalization surpassing $45 billion. Wall Street analysts project the drug could generate more than $9 billion in annual sales by 2032.
First Broadly Effective Oral RAS Inhibitor
The fundamental value of daraxonrasib lies in its unique mechanism of action. RAS, a protein closely linked to tumor growth, is mutated in the vast majority of pancreatic cancer cases, yet researchers have spent years failing to develop drugs that broadly target its various forms. RevMed has employed an innovative "molecular glue" approach that envelops and suppresses this dangerous protein, achieving effective RAS targeting.
Dr. Eileen O'Reilly, an oncologist at Memorial Sloan Kettering Cancer Center and lead author of the pivotal trial, described the approval as "a tremendous advancement" in an interview prior to the FDA's decision. As a once-daily oral tablet, daraxonrasib also promises to enhance the treatment experience—patients can take the medication at home rather than making frequent visits to infusion centers, affording those with incurable disease more precious time with their families. RevMed is also advancing clinical trials to explore the drug's potential in earlier stages of the disease.
High Patient Demand: Over 2,000 Treated Before Launch
Pancreatic cancer carries an exceptionally high mortality rate, with a five-year survival rate of just 13%. According to the American Cancer Society, more than 67,000 Americans will be diagnosed with the disease this year, and over 52,000 will die from it. Market anticipation for the drug was already intense before formal approval. In April, former US Senator Ben Sasse publicly revealed his stage IV pancreatic cancer diagnosis and his use of the drug, drawing widespread attention and more than doubling RevMed's share price since that time.
The urgency among patients and families during the review period was extraordinary. In May, the FDA permitted RevMed to open an expanded access program, allowing patients who did not qualify for clinical trials to obtain the medication. By early August, RevMed reported that over 2,000 patients had received the drug through this program.
FDA Expedited Review Completed, Pricing Yet to Be Announced
On the regulatory front, daraxonrasib also qualified for "ultra-fast review" under the FDA's new voucher program, designed to accelerate the approval process for promising therapies. The FDA stated that this review was completed 6.5 months ahead of the statutory deadline. The approved indication also encompasses patients who are not candidates for systemic therapy. The FDA noted that known side effects of the drug include rash and oral ulcers.